

Original article

Neoadjuvant Chemotherapy plus Surgery versus Direct Surgery in Senile  
Patients with Gastric Cancer

\*Sah Birendra Kumar, Yu Zhenjia, Lu Sheng, \*Li Chen, \*Zhu Zhenggang

Running title: Neoadjuvant Chemotherapy in senile patients

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Authors

### **\*Birendra Kumar Sah, MD/Ph D**

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Postal add: 197 Ruijin Er Road, Shanghai-200025, China

Contact no. : Ph: 0086-21-64370045 ext 671302

Email: rjsurgeon@hotmail.com

ORCID ID: 0000-0002-7415-960X

### **Yu Zhenjia MD/Ph.D. (Co-first author)**

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

### **Lu Sheng MD**

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

### **\*Li Chen, MD/Ph D**

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

### **\*Prof. Zhu Zhenggang, MD/Ph.D., FACS**

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai Key Laboratory of Gastric Neoplasms

Shanghai Institute of Digestive Surgery

Shanghai, China.

**\*Corresponding author**

## Abstract

Background: Despite the lack of decisive research advocating neoadjuvant chemotherapy there is a broad consensus that it is beneficial for gastric cancer in terms of survival. However, there is no comparative research on whether it is similarly helpful in senile patients with the age above 75 years old. Here we compared the survival rate between neoadjuvant plus surgery with direct surgery.

Methods: We analyzed 79 patients with locally advanced gastric cancer who were preoperatively suspicious of serosa positive or beyond (cT4a or cT4b); or extensive lymph node involvement (cN3). Postoperative complications and overall survival rate were compared between the patients who underwent neoadjuvant chemotherapy (NAC) plus surgery and the patients who had direct surgery.

Results: A total of 15 (19%) patients underwent neoadjuvant chemotherapy and 64 (81%) patients had direct surgery. The median follow-up time was 34 months (range of 24-60 months). While the median survival time was not reached in the direct surgery group, the median survival time for the NAC plus surgery Group was 37 months. Two years of overall survival (OS) for the patients in the NAC plus surgery group and direct surgery group were 53.3% and 70.3% respectively. There was no statistical difference between the two groups ( $p > 0.05$ ) in overall postoperative complication and length of

postoperative stay.

Conclusions: Neoadjuvant chemotherapy was feasible in senile patients, there was no difference in survival rate between the patients who had neoadjuvant plus surgery compared to those who had direct surgery. While this result contradicts the previous assumption that neoadjuvant chemotherapy is beneficial for late-stage gastric cancer patients, a well-controlled prospective study is mandatory for a better understanding of whether neoadjuvant chemotherapy is beneficial to senile patients too.

Keywords: gastric cancer; neoadjuvant chemotherapy; senile patients

## **Background**

Neoadjuvant chemotherapy was a highly debated topic for the last two decades, especially between Japan and other Western countries and despite multiple RCTs worldwide (1-4), confusion remains in the field (5, 6). Nevertheless, there is a broad consensus that Neoadjuvant chemotherapy may benefit advanced gastric cancer and it may increase the overall survival rate (7-10). However, most of the past RCTs have not enrolled elderly patients, especially above 75 years of age (11). We carefully conducted a retrospective study to understand whether the Neoadjuvant chemotherapy is similarly beneficial for this group of patients so that we can have a basis to conduct a prospective study to further address this issue. In this work, we compared the overall survival rate between the elderly patients who had received Neoadjuvant chemotherapy plus surgery with the patients who had direct surgery. To achieve as many concrete results from a retrospective study we partially selected only the patients with much-advanced stage, as neoadjuvant chemotherapy is much more controversial in patients with stage II or below, especially in East Asian countries.

## **Methods**

### **Study design**

The primary inclusion criterion was that the elderly patients above 75 years old who had undergone surgical treatment for gastric cancer and completed follow-up for at least 24 months after the treatment. We only included

pathologically confirmed advanced staged gastric cancer patients with clinical staging T4A or T4B or N3, who were preoperatively assessed by computed tomography (CT). The patients with distant metastases were not included. All patients had a performance status of Eastern Cooperative Oncology Group (ECOG)  $\leq 2$  scores. All the patients were treated between January 2018 and December 2021 at Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

In this cohort, the patients were only included if they met all the inclusion criteria and we only collected the data of patients who were included in this study.

### **Treatment**

Patients received chemotherapy for two months before surgery, generally, 3 cycles of chemotherapy were prescribed and the dose of chemotherapy was decreased to 20% less than the standard dose. Standard gastrectomy with curative intent was the principal surgical procedure. It involves resection of at least two-thirds of the stomach with D2 lymph node dissection. Postoperative morbidity and mortality were recorded according to the Clavien-Dindo grading(12).

Overall survival (OS) time in this study is the time from the date of surgery to death from any cause. The data for Relapse-free survival (RFS) was not available accurately, thus not analyzed in this study.

### **Statistical analysis**

The statistical analysis was performed with Statistical Package for Social Science (SPSS) version 22.0 for Windows (SPSS, Inc., Chicago, Illinois). The continuous data are expressed as the median and range. The number of cases was provided for categorical variables. Survival data were presented as the length of overall survival (OS), in months. A Kaplan-Meier plot was created for survival analysis.

## **Results**

The general characteristics of the patients were described in Table 1; the median age was 77 years old in NAC plus Surgery group and 79 years old in the Direct Surgery group. Proximal tumors were more dominant in NAC plus Surgery group than those in the Direct Surgery group ( $p < 0.05$ ). Significantly more patients underwent total gastrectomy in NAC plus Surgery group compared to those in the Direct Surgery group. Altogether 15 patients received neoadjuvant chemotherapy, 60 percent of them had SOX, and 87 percent of patients had three cycles of chemotherapy before the surgery (Table 2). Details on the adverse effects of the chemotherapy were not described due to the lack of actual data due to the retrospective nature of the current study. Details on postoperative pathology were described in Table 3. There was no significant difference ( $p = 0.495$ ) in overall postoperative complications between the two groups (Table 4). All 79 patients had a timely follow-up for two years and above, the median follow-up time was 34 months (range of 24-60 months). Two years of overall survival (OS) for the patients in the NAC group and direct



surgery group were 53.3% and 70.3% respectively. While the median survival time was not reached in the direct surgery group, the median survival time for the NAC Group is 37 months, there was no significant difference between the two groups ( $p=0.294$ ). A Kaplan-Meier plot for OS is provided in Fig.1.

## Discussion

Neoadjuvant chemotherapy has been extensively researched for gastric cancer patients, recently from Germany too (13), and many RCTs advocated for its beneficial effects, including in Japan and China (4,14). However, most of those studies conducted prospective research excluding a group of senile patients, especially those above 75 years (7). Perhaps assuming that those patients might not tolerate preoperative chemotherapy. But we noticed there was a substantial number of patients who underwent surgical treatment for advanced-stage gastric cancer in our center. So there was a scientific question that whether major surgery like radical gastrectomy was better tolerated than neoadjuvant chemotherapy in senile patients. In general, these major surgeries are only performed if the overall organ function is satisfactory for surgical insult. And those criteria are almost similar for evaluating a patient for neoadjuvant chemotherapy. Therefore, we wanted to conduct a prospective study to compare all aspects of results between the patients who undergo neoadjuvant chemotherapy plus surgery with the patients who go for direct surgery. As we did not find such studies in past literature, we conducted this retrospective analysis for a scientific basis to conduct a prospective study.

We intentionally only included relatively late-stage locally advanced gastric cancer patients in this study, so that the result would be more acceptable for the clinician in the region. Despite a clear suggestion in NCCN guidelines suggesting any patients with locally advanced gastric cancer should receive preoperative treatment or neoadjuvant chemotherapy before surgery, neoadjuvant chemotherapy is not well accepted, especially in East Asian countries, and the neoadjuvant chemotherapy is generally administered in patients with relatively late stage (15,16). Therefore, we selected the group of serosa-invaded patients or the patients with extensively enlarged regional lymph nodes.

In general, there is a trend that any prospective study generally enrolls patients below 70 or 75 years old. Thus, the clinical decision for these patients is highly heterogeneous in the different centers and much more dependent on the patient or their family, with the probably prejudiced assumption that these senile patients might not tolerate neoadjuvant chemotherapy. The result shows that these patients tolerated major surgery and the neoadjuvant chemotherapy plus surgery too. This finding incites further research in this field and somehow establishes a thin scientific rationale for more extensive exploration of this particular group of patients.

We believe that the two years overall survival analysis is not enough for reaching any conclusion, however, the result itself is quite interesting that the overall survival rate was much lower in the group of patients who had

neoadjuvant chemotherapy plus surgery, this result contradicts the results in previously published articles. It might be related to the higher number of total gastrectomies in the NAC plus surgery group, there was a significant difference( $p=0.007$ ) in OS rate between the patient with total gastrectomy and partial gastrectomy, and the patients who underwent total gastrectomy had a lower survival rate (Table 5). Besides, we noticed that there were 17 patients in the Direct Surgery group with pathological diagnosis pTNM below stage III. A similar over-diagnosis was earlier reported by Japanese researchers, more than 10 percent of patients with the clinical diagnosis of T3 and T4 were eventually diagnosed with pathological stage I (17). We therefore further calculated the overall survival rate excluding these patients, similarly, there was no significant difference( $p<0.05$ ) between the two groups. And we confirmed that these patients were due to misdiagnosis before surgery. Nevertheless, If the prospective study similarly confirms the results of this study then it will further validate the gut feeling of the surgeons who were reluctant to administer neoadjuvant chemotherapy, especially to these senile patients. Therefore, despite a less number of patients in this cohort and a shorter period of follow-up time we still decided to publish these findings as we consider this would further stimulate more prospective research.

## **Conclusion**

Neoadjuvant chemotherapy was feasible in senile patients, there was no difference in survival rate between the patients who had neoadjuvant plus

surgery compared to those who had direct surgery. Since this result contradicts the previous assumption that neoadjuvant chemotherapy is beneficial for late-stage gastric cancer patients, a well-controlled prospective study is mandatory for a better understanding of whether neoadjuvant chemotherapy is beneficial to senile patients too.

## Declaration

### **Ethics approval and consent to participate**

The study was conducted and analyzed by Unit III of the Gastrointestinal Department, Ruijin Hospital. The study was done according to the Declaration of Helsinki and Good Clinical Practice Guidelines as defined by the International Conference on Harmonisation. The study was approved by the Institutional Review Board of Ruijin Hospital. Patients gave written informed consent for planned treatment.

### **Consent for publication**

The manuscript does not contain any individual data which identifies the patient included in this study.

### **Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

The overall costs of this research will be funded by grants from the National Natural Science Foundation of China No.81772509 (Liu BY), No.81871902 (Su LP), No. 81871904 (Zhu ZG), and No. 82072605 (BY Liu).

### **Author contributions**

BKS designed the study, collected the patient data, and drafted the

manuscript.ZJY followed up with patients for overall survival. SL assisted in data collection from the central database of the unit.CL and ZGZ participated in the design of the study and critically revised drafts of the manuscript. All authors meet the criteria for publication; all authors have read and approved the final manuscript.

### **Acknowledgments**

The authors thank all the clinicians in the gastrointestinal department for their support to conduct this study.

## References

1. Cunningham D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med*. 2006;355(1):11-20.
2. Schuhmacher C. et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. *J Clin Oncol*. 2010;28(35):5210-8.
3. Li, W. et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. *World J. Gastroenterol*. 16, 5621–5628 (2010).
4. Tokunaga M. et al. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. *Surg Today*. 2020 Jan;50(1):30-37.
5. Reddavid R. et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? *World J Gastroenterol*. 2018 Jan 14;24(2):274-289.
6. Iwasaki Y. et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. *Gastric Cancer*. 2021 Mar;24(2):492-502.
7. Li, W. et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. *World J. Gastroenterol*. 16, 5621–5628 (2010).
8. Ronellenfitsch, U. et al. Perioperative chemo (radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. *Cochrane Database Syst Rev*. CD008107

(2013).

9. Zhao, J. H. et al. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. *BMC Cancer* 16, 631 (2016).

9. Eto, K. et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. *Gastric Cancer* 21, 703–709 (2018).

11. Joharatnam-Hogan N. et al. Challenges in the treatment of gastric cancer in the older patient. *Cancer Treat Rev.* 2020 Apr;85:101980.

12. Dindo D. et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.* 2004 Aug;240(2):205-13.

13 Al-Batran SE. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet.* 2019 May 11;393(10184):1948-1957.

14. Zhang X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. *Lancet Oncol.* 2021 Aug;22(8):1081-1092.

15. Katayama H. et al. An integrated analysis of two phase II trials (JCOG0001



and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. *Gastric Cancer*. 2019 Nov;22(6):1301-1307.

16. Takahari D. et al. Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). *Gastric Cancer*. 2020 Mar;23(2):293-299.

17. Fukagawa T. et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). *Gastric Cancer*. 2018 Jan;21(1):68-73.

Table 1 Demographic Data

Parameter		NAC plus Surgery	Direct Surgery	P Value
Sex	Male	12 (80.0)	41 (64.1)	0.237
	Female	3 (20.0)	23 (35.9)	
Age (years)	Median	77	79	0.217
	Range	76-85	76-89	
Body mass index	Median	22.49	21.66	0.336
Site of tumor	Proximal	8 (53.3)	13(20.3)	0.041*
	Body	4 (26.7)	22 (34.4)	
	Distal	3 (20.0)	29 (45.3)	
cTNM stage	III	14(93.3)	56(87.5)	0.456
	IVA	1(6.7)	8(12.5)	
R0 Resection	Yes	14 (93.3)	59 (92.2)	0.681
	No	1 (6.7)	5(7.8)	
Type of Gastrectomy	Partial	4 (26.7)	46(71.9)	0.002
	Total	11 (73.3)	18(28.1)	

---

\*Fisher's Exact Test

Table 2 Preoperative Chemotherapy

Regimen	Number of patients	Chemotherapy cycles
SOX	7	3
SOX	1	2
SOX	1	4
EOX	2	3
S1	2	3
PS+PD1	1	3
S1+PD1	1	3

Table 3 Postoperative Pathology

Parameter	Stage	NAC plus Surgery	Direct Surgery
ypTNM	pCR	1	NA
	I	2	NA
	II	4	NA
	III	8	NA
pTNM	IA	NA	2(3.1)
	IIA	NA	4(6.3)
	IIB	NA	11(17.2)
	IIIA	NA	23(35.9)
	IIIB	NA	14(21.9)
	IIIC	NA	10(15.6)

Table 4 Postoperative Complications

Complication	NAC plus Surgery	Direct Surgery
Overall complications	6(40.0)	23(35.9)
Grade 0- I	9(60.0)	41 ( 64.1 )
Grade II	4 ( 26.7 )	15 ( 23.4 )
Grade IIIa	2 ( 13.3 )	3 ( 4.7 )
Grade IVa	0	4 ( 6.2 )
Grade V	0	1 ( 1.6 )
Surgical complication	5(33.3)	21(32.8)
Intra-abdominal hemorrhage	1(6.7)	1(1.6)
Reoperation	0	3 ( 4.7 )
Anastomotic leakage	1 ( 6.7 )	5(7.8)
Duodenal stump leak	0	2(3.2)
Anastomotic bleeding	1(6.7)	0
Pulmonary Infection	2(13.3)	8(12.5)
Abdominal Infection	4(26.7)	16(25.0)
Urinary tract infection	0	1
Central line infection	1(6.7)	
Bloodstream infection	1(6.7)	2(3.2)
Wound infection	1(6.7)	1(1.6)
Pancreatic fistula	1 ( 6.7 )	2(3.1)
Death	0	1

Table 5 Survival risk factors

		Alive	Dead	P Value
Treatment	NAC plus Surgery	6(40.0)	9(60.0)	0.212
	Direct Surgery	37(57.8)	27(42.2)	
Gastrectomy	Total	10(34.5)	19(65.5)	0.007
	Partial	33(66.0)	17(34.0)	
Tumor Site	Proximal	10(47.6)	11(52.4)	0.624
	Body	16(61.5)	10(38.5)	
	Distal	17(53.1)	15(46.9)	
cTNM Stage	III	40(57.1)	30(42.9)	0.177
	IVA	3(33.3)	6(66.7)	

Figure legends

Fig.1 Kaplan-Meier (K-M) Plot for OS

